Skip to main content

Table 1 Baseline Characteristics

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics Total Population Age categories
1–6 years 6–12 years > 12 years
Number of Patients 30 8 14 8
Female/Male 13/17 2/6 6/8 5/3
Age (years) 9.23 ± 3.942 4.54 ± 0.962 9.07 ± 1.619 14.22 ± 2.229
Weight (kg) 30.11 ± 13.161 18.11 ± 4.209 29.10 ± 10.627 43.88 ± 10.346
Weight (SDS) − 0.15 ± 1.41 0.27 ± 1.35 − 0.06 ± 1.00 − 0.59 ± 0.78
Height (cm) 130.09 ± 18.906 108.19 ± 9.494 130.14 ± 11.374 151.89 ± 7.691
Height (SDS) −0.04 ± 1.13 0.39 ± 1.56 −0.27 ± 1.39 −0.54 ± 1.15
BMI (kg/m2) 16.99 ± 3.364 15.28 ± 1.274 16.79 ± 3.297 19.04 ± 4.108
BMI (SDS) 0.04 ± 0.97 0.04 ± 0.81 0.10 ± 0.91 −0.43 ± 0.89
HbA1c (%) 9.65 ± 1.998 8.59 ± 0.753 10.32 ± 2.213 9.53 ± 2.159
FPG (mg/dL) 156.93 ± 42.373 136.50 ± 12.862 176.43 ± 49.781 143.25 ± 34.919
Insulin dose (U/kg of body weight/day)
 Basal insulin 0.42 ± 0.134 0.38 ± 0.120 0.46 ± 0.165 0.40 ± 0.069
 Bolus dose 0.49 ± 0.208 0.37 ± 0.115 0.57 ± 0.255 0.48 ± 0.128
  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SDS Standard Deviation Score
\